Results 241 to 250 of about 3,108,169 (356)

Delineation and monitoring of the T cell repertoire of adoptive cell transfer product during the treatment of advanced melanoma. [PDF]

Genome Med
Kerr C, Soleimani S, Mulder DT, Nabbi A, Gray D, Pedersen S, Sotov V, Sudhaman S, Nguyen L, Hirano N, Ohashi PS, Butler MO, Pugh TJ.   +12 more
europepmc   +1 more source

The Role of miRNAs in Chicken Immune Regulation and Prospects for Disease‐Resistant Breeding

Animal Research and One Health, EarlyView.
A schematic workflow illustrating the screening of disease‐resistant miRNAs and the generation of miRNA‐based disease‐resistant chickens via PGC‐mediated germline genome editing. ABSTRACT MicroRNAs (miRNAs) are emerging as pivotal regulators of the immune system, playing a decisive role in shaping disease resistance in chicken.
Qiangzhou Wang, Weiran Wu, Qingqing Cai, Jiaxing Wang, Qi Gao, Muhammad Iftikhar, Yulin Bi, Hao Bai, Lihong Gu, Guobin Chang, Shihao Chen   +10 more
wiley   +1 more source

Perioperative Pembrolizumab in Locally Advanced Melanoma: A Real-world Single-centre Retrospective Study.

Acta Derm Venereol
Goller S, Dege T, Schummer P, Haug L, Meir M, Gehrke T, Klein D, Goebeler M, Kneitz H, Schilling B, Gesierich A, Glutsch V.   +11 more
europepmc   +1 more source

Antibiotic Exposure Does Not Impact Anti-BRAF/Anti-MEK Targeted Therapy Outcome in Patients with Advanced Melanoma. [PDF]

Curr Oncol
Wang YS, Wang QY, Moise AE, Syed HC, Malo J, Soberano S, Belkaid W, Messaoudene M, Bélanger K, Desilets A, Jamal R, Routy B, Elkrief A.   +12 more
europepmc   +1 more source

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.

The Lancet Oncology, 2016
F. Hodi, J. Chesney, A. Pavlick, C. Robert, K. Grossmann, D. McDermott, G. Linette, N. Meyer, J. Giguere, S. Agarwala, M. Shaheen, M. Ernstoff, D. Minor, A. Salama, Matthew H. Taylor, P. Ott, C. Horak, P. Gagnier, Joel Jiang, J. Wolchok, M. Postow   +20 more
semanticscholar   +1 more source

A Multifaceted Interplay Among Hemophagocytosis, Interleukin‐18, and Type I Interferon Distinguishes Still Disease From Other Autoinflammatory Diseases

Arthritis &Rheumatology, EarlyView.
Objective The unknown pathophysiology and the lack of specific features for systemic juvenile idiopathic arthritis and adult‐onset Still disease (collectively known as Still disease; SD) delay diagnosis and appropriate treatment. The goal of this study was to identify features and mechanisms that distinguish SD from other systemic autoinflammatory ...
Yvonne M. Mueller, Charlotte Girard, Harmen J. G. van de Werken, Stefan J. Erkeland, Dwin G. B. Grashof, Laurie Vaillant, Renske J. H. den Dekker, Iris van Zuijen, Sharon Veenbergen, Fanny Coffin, Eric Bindels, Yvan Jamilloux, Katerina Laskari, Vassili Soumelis, Bruno Fautrel, Cem Gabay, Peter D. Katsikis   +16 more
wiley   +1 more source

Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801. [PDF]

Clin Transl Oncol
Espinosa E, Berciano-Guerrero MÁ, Muñoz-Couselo E, Puértolas T, Manzano JL, Soria A, de Miguel PA, Crespo G, Sanz LG, Cerezuela-Fuentes P, de la Rosa CA, Majem M, Castaño AG, Berrocal A, Arroyo FRG, de la Borbolla MR, Bellido L, Martínez JM, Fernández LA, Carnicero AM, Castro RL, Rodríguez AB, Lecumberri MJ, Guzmán JCV, Balea BC, Rodríguez JF, Bautista JV, Pérez VN, Mujika K, Subias MC, Hernández B, Algarra SM, Márquez-Rodas I.   +32 more
europepmc   +1 more source

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source

Current Treatment Paradigms for Advanced Melanoma with Brain Metastases. [PDF]

Int J Mol Sci
Bonzano E, Barruscotti S, Chiellino S, Montagna B, Bonzano C, Imarisio I, Colombo S, Guerrini F, Saddi J, La Mattina S, Tomasini CF, Spena G, Pedrazzoli P, Lancia A.   +13 more
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source